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Summary most common of the acute hepatic porphyrias, and
the prevalence of the disease has been estimated at 1/
Acute intermittent porphyria (AIP) is the major autoso-
10,000 in different countries (Bonkowsky 1982; Kap-
mal dominant form of acute hepatic porphyrias. The
pas et al. 1995).
disease is due to mutations in the gene encoding for
PBG deaminase is encoded by a single 11-kb geneporphobilinogen (PBG) deaminase and is characterized
located in chromosomal region 11q24.1-11q24.2by life-threatening neurovisceral attacks, often precipi-
(Namba et al. 1991). The gene contains 15 exons withtated by drugs, fasting, cyclical hormonal changes, or
a size range of 39–438 bp (Yoo et al. 1993). Twoinfectious diseases. This report describes a prospective
distinct mRNAs are produced by the alternative splic-study on the molecular epidemiology of PBG deaminase
ing of two primary transcripts arising from two pro-gene defects in AIP. It uses a sensitive, reliable, and easy-
motors. The upstream promotor is active in all tissues,to-handle method for routine AIP molecular diagnosis
and the housekeeping transcript initiated by this pro-and family study based on an exon-by-exon denaturing
moter is encoded by exons 1 and 3–15. The othergradient gel electrophoresis (DGGE) strategy followed
promotor lies 3 kb downstream in intron 1 and is ac-by direct sequencing. Fifteen genomic DNA fragments,
tive only in erythroid cells. Its utilization produces aincluding all the coding sequence and covering 3.35 kb
transcript encoded by exons 2–15 (Grandchamp etof the PBG deaminase gene, were investigated in 405
al. 1987). In classical AIP the housekeeping and thesubjects from 121 unrelated French Caucasian AIP fami-
erythroid-speciﬁc enzymes both have half-normal ac-lies who had not been screened previously at the DNA
tivities in erythroid and nonerythroid tissues, whereaslevel. PBG deaminase gene mutations were identiﬁed in
in the variant, nonerythroid form of the disease the109 families, but only 78 were of different type, and
enzymatic defect is present only in nonerythroid cellseach of them had a prevalence rate õ5%. Among these
and is caused by molecular defects in exon 1 (Musta-mutations, 33 had not been published previously. Sixty
joki 1981; Mustajoki and Desnick 1985; Wilson et al.percent of these 78 mutations were located in only three
1986; Grandchamp et al. 1989b, 1989c).exons (exons 10, 12, and 14), 44% were missense, 18%
Clinical onset of the disease is characterized by inter-were splice defect, 19% were frameshift, and 16% were
mittent attacks of neurological dysfunction, includingnonsense. In addition, two de novo mutational events
abdominal pain and neuropsychiatric symptoms. Diag-were characterized. The evaluation of the efﬁciency of
nosis of AIP in patients is readily done by detection ofthe standard PBG deaminase enzymatic screening
the urinary overproduction of porphyrin precursors, dmethod for gene-carrier detection indicated 95% of con-
aminolevulinic acid (ALA) and PBG (Lamon et al.cordancy with the molecular-based diagnosis.
1977). The clinical expression shows intra- and interin-
dividual variability. Presymptomatic diagnosis of AIP
Introduction gene carriers is essential to prevent acute, life-threaten-
ing neurological attacks, by avoidance of known precipi-Acute intermittent porphyria (AIP) is an autosomal
tating factors such as drugs, alcohol, and fasting (Kap-dominant disorder caused by a 50% reduction in the
pas et al. 1995). When the patients are informed andactivity of PBG deaminase (E.C.4.3.1.8), the third en-
precipitating factors are avoided, only 10%–20% ofzyme in the heme biosynthetic pathway. AIP is the
the patients present acute attacks, yet 50% have milder
symptoms during their lifetime (Kauppinen and Musta-
joki 1992). Asymptomatic patients do not consistentlyReceived November 13, 1996; accepted for publication March 10,
1997. excrete excess amounts of ALA and PBG, and the usual
Address for correspondence and reprints: Dr. YvesNordmann,Hoˆp- screening method in AIP families is based on measure-
ital Louis Mourier, 92701 Colombes Cedex, France.
ment of erythrocyte PBG deaminase activity (Meyer et 1997 by The American Society of Human Genetics. All rights reserved.
0002-9297/97/6006-0015$02.00 al. 1972). Diagnosis by this enzymatic assay is not un-
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ambiguous, because of a signiﬁcant overlap between car- PBG Deaminase Assay
rier values and control values (Sassa et al. 1974; Bonaiti- The assay measures the kinetic development of uro-
Pellie et al. 1984). In addition, subjects with a nonery- porphyrin ﬂuorescence produced from PBG, as de-
throid variant form of AIP cannot be detected, because scribed elsewhere (Meyer et al. 1972), with slight modi-
they have a normal erythrocyte PBG deaminase activity ﬁcations. In brief, the erythrocytes from EDTA-
(Mustajoki 1981). anticoagulated blood were washed in 8.5% saccharose.
DNA analysis is a potentially useful alternative The packed cells were lysed by addition of 10 vol of
method for establishing the status of individuals for 0.1 mol Tris-HCL buffer pH 8.0/liter, containing 0.2%
whom enzyme measurements give equivocal results. Triton X-100. The hemoglobin concentration was mea-
However, the molecular diagnosis of AIP is complicated sured by the cyanmethemoglobin method (Boehringer
by the large allelic heterogeneity, with 81 different muta- Mannheim). The reaction mixture contained 25 ml of
tions in the PBG deaminase gene reported to date (for lysate, 200 ml of 0.1 mmol Tris-HCL buffer pH 8.0/
review, see Deybach and Puy 1995; also see Kauppinen liter, and 25 ml of 1 mmol PBG/liter. After incubation
et al. 1995; Lundin et al. 1995; Morita et al. 1995; in the dark for 60 min at 37C, the reaction was stopped
Schreiber at al. 1995; Ong et al. 1996; Puy et al. 1996). by addition of 1 ml of 10% trichloracetic acid.
In The Netherlands and Sweden, a limited number of After centrifugation at 10,000 g for 5 min, the super-
mutations occur in most AIP families (Lee and Anvret natant ﬂuorescence emission (excitation at 405, emis-
1991; Gu et al. 1993, 1994). However, in Finland a sion at 655) was measured on a Shimadzu RF-540
high heterogeneity of AIP mutations has been reported spectroﬂuorometer ﬁtted with a red-sensitive photomul-
(Kauppinen et al. 1995). tiplier and was converted to picomoles of uroporphyrin,
In this study, we prospectively investigated 121 with uroporphyrin I (Sigma) used as a standard. The
French Caucasian AIP families including 405 members enzymatic activity was expressed as picomoles of uro-
seen at the Centre Franc¸ais des Porphyries during 1992– porphyrin formed per hour per milligram of hemoglobin
95 who were clinically and biochemically well charac- (Hb) at 37C. Mean { SD PBG deaminase activity in
terized. The sensitivity and speciﬁcity of the denaturing controls (n Å 150) was 125{ 20 pmol of uroporphyrin/
gradient gel electrophoresis (DGGE) method for screen- h/mg Hb at 37C. The intraassay coefﬁcient of variation
ing mutations in all the 15 exons and exon/intron was 3% (n Å 30), and the interassay coefﬁcient of varia-
boundaries of the PBG deaminase gene were evaluated. tion was 6% (n Å 25). The enzyme activity cutoff for
The molecular epidemiology of the Caucasian AIP co- the AIP gene carrier has been established at 85 pmol
hort was determined, and the efﬁciency of the molecular- uroporphyrin/h/mg Hb at 37C (mean normal value mi-
biology method for AIP diagnosis was compared with nus 2 SD) (Bonaiti-Pellie et al. 1984). According to pre-
that of the standard enzymatic method. vious studies, children õ1 year old, as well as samples
with reticulocyte count ú3%, were excluded from the
enzymatic screening (Sassa et al. 1974; Bonaiti-Pellie etPatients and Methods
al. 1984; Astrin and Desnick 1994).
Patients
Detection of PBG Deaminase Gene SequenceAll the AIP families included in the study were diag-
Variation by DGGEnosed in the Centre Franc¸ais des Porphyries during
1992–95, and patients from each AIP family were fol- Genomic DNA was prepared from peripheral leuko-
cytes or lymphoblastoid cells as described elsewhere (Hi-lowed up clinically in the center. A total of 405 subjects
from 121 unrelated French AIP families of Caucasian guchi 1990). DNA was ampliﬁed by PCR in an auto-
mated DNA thermal cycler (Kontron) by use of Taqorigin were subjected to both erythrocyte PBG deami-
nase activity measurement and molecular analysis of the polymerase (Beckman). Fifteen different PCR products
for 15 DGGE analyses were designed to cover the wholePBG deaminase gene. These families represented ap-
proximately one-third of the French AIP population coding sequence of the PBG deaminase gene and ú50
bp upstream and downstream of each exon/intronknown in 1995. The diagnosis of AIP was based on
typical clinical symptoms, with increased urinary excre- boundary. This exon-by-exon strategy allowed screen-
ing of 3.35 kb of the 11 kb of the chromosomal PBGtion of the heme precursors ALA and PBG, normal fecal
porphyrin excretion, and (except in two AIP families deaminase gene. DGGE was performed according to the
method of Myers et al. (1987). Computer analyses werewith a nonerythroid form of the disease) a well-docu-
mented decrease in PBG deaminase activity in erythro- performed with the MELT 87 and SQHTX programs
written and kindly provided by Lerman and Silversteincytes (Stein and Tschudy 1970). This AIP cohort in-
cluded four patients whose mutations already had been (1987). These programs were used to select the positions
of PCR primers and the optimal experimental conditionsreported in a previous ‘‘short communication’’ (Puy et
al. 1996). for DGGE analysis. One of the two ampliﬁcation prim-
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ers of each pair bore an additional GC-rich sequence at linearly increasing denaturant gradient (100% denatur-
ant: 7 mol/liter urea/40% formamide). For each exonicits 5 extremity (table 1), in order to create an artiﬁcial
high-temperature melting domain in the PCR product fragment explored by DGGE, we systematically loaded
on the gel a homozygous normal control and a heterozy-(Shefﬁeld et al. 1989). For each patient, all 15 exons and
their surrounding intron sequences were systematically gous mutated control for the DNA sequence under study
(see legend to ﬁg. 1). This was done to avoid any techni-analyzed by DGGE, to eliminate the possibility of an-
other sequence variation and to ensure that a detected cal problem during either the formation of gel gradients
or the electrophoretic migration. On the DGGE gels,base substitution could not be due to a polymorphism.
Aliquots (10 ml) of each ampliﬁed DNA were separated migration of alleles from a homozygous normal subject
gave a single band representing the normal homoduplexby electrophoresis in an 8% polyacrylamide gel with a
Table 1
Sequence of Oligonucleotide Primers and Conditions Used in PCR and DGGE Analysis of All PBG Deaminase Exons
PCR CONDITIONS
SIZE MgCl2 Temperature DGGE
EXON(S) AND PRIMER 5-SEQUENCEa (bp) (mM) ( C) CONDITIONSb
1:
Human PBG deaminase exon 01 sense clamped (GC)30-CGTGTCCCCGGTACTCGCC 203 1.5 60 50%/80%, 6 h
Human PBG deaminase intron 01 antisense CTCGTCCAGAAGCCCAAAGTGTG
2:
Human PBG deaminase intron 02 sense CCACTGACAACTGCCTTGGTCAA
217 1.0 60 50%/80%, 3 h
Human PBG deaminase intron 02 antisense clamped (GC)50-GAAATACTCCAAGGCTGGTCCT
3:
Human PBG deaminase intron 02 sense clamped (GC)50-GCCAGTGATTCTGGTTCTTGGAC 257 1.5 57 45%–75%, 3 h
Human PBG deaminase intron 03 antisense TCCCCCAATTTGTGATGCTGT
4:
Human PBG deaminase intron 03 sense AAGAGTCTGAGCCGTGGCTGG
233 1.0 57 50%/80%, 31/2 hHuman PBG deaminase intron 04 antisense clamped (GC)35-GTTGTGTTCTCTCCTCTCGGGG
5 and 6:
Human PBG deaminase intron 04 sense AAATGCTGATCAATAATGAGCACCT
308 1.0 55 40%/90%, 4 h
Human PBG deaminase intron 06 antisense clamped (GC)40-CTGGGAGGGCACCACACTCTCC
7:
Human PBG deaminase intron 06 sense clamped (GC)45-TGGCTGCTCATACCCTTTCTCT 215 1.0 56 40%/90%, 3 h
Human PBG deaminase intron 07 antisense ATGATGCCTACCCCTGCCCA
8:
Human PBG deaminase intron 07 sense clamped (GC)45-AATCGAGAGAGAATAGAGGTGAT 254 1.0 56 50%/80%, 3 h
Human PBG deaminase intron 08 antisense TCCCATCCCTGCATCTTCTGG
9:
Human PBG deaminase intron 08 sense ATCTCATTGTAACTTCTCTCTGGGC
215 1.0 55 50%/80%, 31/2 hHuman PBG deaminase intron 09 antisense clamped (GC)40-CTTGTCTTTTTCCTTGGCTGCT
10:
Human PBG deaminase intron 09 sense CCGACACTGTGGTCCTTAGCAA
250 1.0 56 50%/80%, 3 h
Human PBG deaminase intron 10 antisense clamped (GC)45-TGGGGATGACTGTAAGGCAGA
11:
Human PBG deaminase intron 10 sense CTGCCAGGTGCTTTTAGACA
185 1.0 58 55%/90%, 3 h
Human PBG deaminase intron 11 antisense clamped (GC)45-AGGCATATGTCACCATGTGG
12:
Human PBG deaminase intron 11 sense clamped (GC)50-CAGGCCTGATGTCCTAGGATGT 235 1.0 55 40%/70%, 3 1/4 hHuman PBG deaminase intron 12 antisense TCCCCAGCCCTCCACAGGT
13:
Human PBG deaminase intron 12 sense clamped (GC)45-TTGTGTATGGATAGGACCAG 298 1.0 55 40%/90%, 3 h
Human PBG deaminase intron 13 antisense CTACCTAGAAACCTGGGATG
14:
Human PBG deaminase intron 13 sense clamped (GC)45-TAGTCCCCTCTCAGACTGTG 220 1.0 55 55%/90%, 31/2 hHuman PBG deaminase intron 14 antisense ATGCACTCTTGTTTATTACCCC
15:
Human PBG deaminase intron 14 sense TCACCAAATCCCACCTCCTTCCC
315 1.0 61 45%/75%, 31/2 hHuman PBG deaminase exon 15 antisense clamped (GC)40-GAATGGGGCACTGAGGCCCG
a Sequences of GC clamps are as follows: (GC)30, CGCCCGCCGCGCCCCGCGCCCGTCCCGCCG; (GC)35, CGCCCGCCGCGCCCCGCGCCCGTCCCGCCG-
CCCCC; (GC)40, CGCCCGCCGCGCCCCGCGCCCGTCCCGCCGCCCCCGCCCG; (GC)45, CGCCCGCCGCGCCCCGCGCCCGTCCCGCCGCCCCCGCCC-
GCCCCC; and (GC)50, CGCCCGCCGCGCCCCGCGCCCGTCCCGCCGCCCCCGCCCGCCCCCGCCCG.
b Percentages are of denaturant (100% Å 7 M urea and 40% [v/v] formamide), and time is of electrophoresis (at 150 V and 60C).
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and D21S226). Sequence information and PCR condi-
tions were obtained from Genome Data Base (Gyapay
et al. 1994).
Results
DGGE Analysis of the PBG Deaminase Gene
All coding sequences and exon/intron boundaries of
Figure 1 DGGE as a screening procedure. In this example, the human PBG deaminase gene could be screened by
DGGE analysis was used to screen mutations in four exons of the
DGGE. The mutation study in AIP families was con-PBG deaminase gene from six patients (P1–P6) of newly diagnosed
ducted by use of a two-step strategy: all 15 exons wereAIP families. For each exon screened, a negative control with a normal
homozygous DNA sequence (C0) and a positive control with a known ﬁrst explored in one patient from each newly diagnosed
mutated or polymorphic heterozygous DNA sequence (C/) were AIP family whose mutation had not yet been determined
loaded onto the gel and were run under the same experimental condi- (ﬁg. 1). When a sequence variation was detected by
tions as were used for patients (primers and DGGE procedure are
DGGE and, by direct sequencing, was characterized fur-indicated in table 1). The course of mutation analysis for each patient
ther as a mutation, all the family members were investi-sample was as follows: DNA extraction, separate ampliﬁcation of the
15 exons, DGGE of the 15 exons, and direct sequencing of fragments gated by DGGE analysis of the affected exon (ﬁg. 2). In
with abnormal DGGE pattern. each DNA fragment that presented an abnormal DGGE
pattern, a sequence variation (either a mutation or a
polymorphism) was always characterized by further di-
rect sequencing. Among the 121 unrelated AIP familieswhereas, that from heterozygous mutated subjects ex-
studied, a PBG deaminase gene mutation could be identi-hibited three or four bands; the two lower bands corre-
ﬁed in 109 families. However, in 12 remaining AIP pa-sponded, respectively, to the normal and mutated homo-
tients from 12 unrelated families, the DGGE screeningduplexes, and the upper bands corresponded to the two
was completely normal; and all the exons and exon/types of mutant/normal heteroduplexes (ﬁg. 1). The elec-
intron junctions were sequenced, and no base change ortrophoretic migration proﬁle produced by each speciﬁc
sequence alteration was found.heterozygous sequence variation in a given ampliﬁed
DNA fragment was reproducible between runs, with
Molecular Epidemiology of PBG Deaminase Genesmall variations in the distance between homo and heter-
Defects in AIPoduplexes. The primer sequences, hybridization temper-
ature for each PCR, and the electrophoretic conditions In 109 AIP families, a total of 78 different types of
used for DGGE analysis are given in table 1. mutation were characterized, 33 of which had not been
Genomic DNA Sequencing
Abnormal DNA homodimeric bands were isolated
from the DGGE gels and were directly sequenced by
use of 35S-dATP and the fMol DNATM sequencing kit
(Promega-Biotech). The mutations were conﬁrmed fur-
ther by sequencing of ampliﬁed products from genomic
DNA, with different primers as used for DGGE analysis.
In addition, to limit the risk that the detected base
change could be a rare polymorphism, §200 French
control samples were screened by DGGE, to avoid simi-
lar abnormal migration pattern in normal subjects.
Reverse-Transcription PCR
When a splice-site disruption was detected, RNA
isolated from lymphoblastoid cells was studied by re- Figure 2 DGGE as a diagnostic procedure. After characteriza-
verse-transcription PCR, to conﬁrm exon skipping tion of the mutation by direct sequencing, DGGE analysis was used
to detect gene carriers in a family with the nonerythroid form of AIP.(Higuchi 1990).
Normal individuals showed the normal homodimeric band, whereas
a pattern of three bands was observed in patients and asymptomaticDNA Microsatellite Analysis
gene carriers. Completely blackened symbols denote patients with
In suspected de novo AIP cases, nonpaternity was overt AIP; and half-blackened symbols denote asymptomatic carriers.
excluded by genotyping at six highly polymorphic loci The sequential steps for each sample analysis were as follows: DNA
extraction and one PCR followed by one DGGE of the affected exon.(D12S89, D12S364, D12S358, D12S320, D21S11,
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reported elsewhere. These 78 different mutations are protein (R26H). The patient was the only member of
the family who was known to have AIP symptoms. Nei-listed in table 2.The mutations were spread over all ex-
ons (except exon 2) of the PBG deaminase gene. Most ther of the patient’s parents was a carrier of the muta-
tion, and their urinary and enzymatic analyses were alsoof them were ‘‘family speciﬁc’’—that is, were found in
only one pedigree; however, four were found to have a normal. Nonpaternity was excluded by DNA microsat-
ellite analysis (see Patients and Methods).slightly higher prevalence (Ç5%): two missense muta-
tions (R167W and E250K), one nonsense mutation
Molecular Diagnosis versus Enzymatic Screening(R149X), and one splice-site disruption in exon 14 (a
in AIPGrA transition at position 912/1). Two yet-unde-
scribed families had a mutation in exon 1, leading to a When a mutation in the PBG deaminase gene was
nonerythroid form of AIP: one had a mutation already characterized in one AIP patient, relatives within the
described in a Finnish patient (i.e., an exon 1 splicing family were screened by use of a single PCR ampliﬁca-
defect due to GrT transversion at position 33; tion followed by a single DGGE of the mutated exon
Grandchamp et al. 1989b); and the other mutation was (ﬁg. 2). This strategy allowed us to determine the molec-
similar to the Dutch type (exon 1 splicing defect due to ular status of 385 members from the 109 characterized
GrA transition at position 33/1; Grandchamp et al. AIP families and to accurately classify them into three
1989c). In the classical form of AIP, 60% of the muta- groups (patients, asymptomatic gene carriers, and nor-
tions were located in exons 10, 12, and 14. Of the 78 mal subjects). The molecular diagnosis was then com-
mutations, 61 were single base substitutions (35 mis- pared with the previous, enzyme-based diagnosis. The
sense mutations, 14 splice defects, and 12 nonsense mu- PBG deaminase activities of the members of the three
tations), and 17 were base deletions or insertions (15 groups are plotted in ﬁgure 3. It appeared that, in 95%
were frameshifts [10 of which were deletions and 5 of of cases (240/252; ﬁg. 3), the AIP gene–carrier status
which were insertions], 1 was a 21-bp in-frame duplica- based on the PBG deaminase enzymatic activity was
tion, and 1 was a 30-bp deletion). Point mutations af- conﬁrmed by the molecular diagnosis. Indeed, the two
fected a G or a C in 84% of cases, and CpG dinucleo- families with the nonerythroid variant form of AIP (23
tides were involved in 52% of cases (table 2). Among individuals), whose carrier status could be established
the 35 missense mutations found, 10 were newly de- only by DNA analysis, were excluded from the concor-
scribed; 8 of these 10 involved evolutionarily invariant dance study.
amino acid residues, and the remaining 2 (H256Y and
A270D) were likely to change local hydrophobicity and Discussion
charge pattern. In addition, all of them cosegregate with
erythrocyte PBG deaminase activity in the affected fami- Before this study, a total of 81 different mutations in
the PBG deaminase gene had been reported as causinglies, through at least two generations. These results
strongly suggest that these gene defects were directly AIP. To date, only one systematic and extensive study
has been performed on a large scale, in Finland: 28causative of disease. Arginine or glutamic acid were re-
placed in 16 of the 35 missense mutations (table 2). The AIP families were screened by SSCP, and 19 different
mutations were reported (Kauppinen et al. 1995).glutamic acid at position 250 was implicated in several
mutations (E250Q, E250K, E250V, and E250A), as Using DGGE, we screened 15 DNA segments covering
one-third of the chromosomal PBG deaminase gene, in-were the arginines at positions 149, 167, and 173
(R149X, R149Q, and R149L; R167W and R167Q; and cluding the complete coding sequence. Among the 121
unrelated AIP families analyzed, mutations were identi-R173W and R173Q). The functional consequences of
the 14 mutations modifying splice sites were conﬁrmed ﬁed in 109. In 12 families, DGGE screening of patients’
genomic DNA was negative, and direct sequencingby the demonstration of a shortened mRNA (data not
shown): in 10 of these mutations, exon skipping resulted failed to detect any mutation in the corresponding se-
quences. However, in all these cases, there was a well-from donor splice-site mutations, and in the 4 others it
resulted from acceptor splice-site mutations. No new documented PBG deaminase enzyme deﬁciency, which
segregates through three generations (not shown); there-polymorphism was found in any coding or intronic se-
quence explored by DGGE. fore, the causative mutation probably lies in an unex-
plored part of the gene. When these later cases are taken
De Novo Case into account, the sensitivity of the DGGE method is
§90% when applied to a large heterogeneous AIP co-DGGE analysis of the DNA from one AIP patient gave
an abnormal mobility pattern only in exon 3. Direct hort. Alternative methods—SSCP and heteroduplex
analysis—also have been applied to PBG deaminasesequencing of the corresponding genomic DNA frag-
ment showed only a GrA transition at position 77, lead- gene mutation screening (Kauppinen et al. 1995;
Schreiber et al. 1995). SSCP requires the use of multipleing to replacement of an arginine by histidine in the
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Table 2
Mutations in PBG Deaminase Gene in 109 French AIP Families
Restriction
Position Mutationa Sequence Modiﬁcationb Enzyme Reference
Exon 1:
33 GCGrGCT SD (del exon 1) HphI Grandchamp et al. (1989b )
Intron 1:
33 /1 gtgratg SD (del exon 1) . . . Grandchamp et al. (1989c )
Exon 3:
64 CGGrTGC R22C . . . Ong et al. (1996)
70 GGTrAGT G24S . . . Present study
76 CGCrTGC R26C BspMI Kauppinen et al. (1995)
77 CGCrCAC R26H . . . Llewellyn et al. (1993)
83 AGCrAAC S28N . . . Present study
Exon 4:
91 CGCTrCACT A31T . . . Gu et al. (1994)
100 CAGrAAG Q34K . . . Mgone et al. (1992)
108 GACrGAT D36D . . . Present study
125 TTGrTAG L42X . . . Puy et al. (1996)
158 ins A Frameshift (stoprcod /12) . . . Present study
Intron 4:
160 /1 gtgrttg SD (del exon 4) . . . Present study
Exon 5:
163 GCTrTCT A55S . . . Gu et al. (1994)
174 del C Frameshift (stoprcod /40) . . . Gu et al. (1994)
182 ins G Frameshift (stoprcod /5) . . . Gu et al. (1994)
206–207 del CT S69X . . . Present study
Intron 5:
210 /1 gtarata SD (del exon 5) MaeIII Gu et al. (1994)
210 /2 ins G SD (del exon 5) . . . Present study
Exon 6:
218–219 del AG Frameshift (stoprcod /9) . . . Gu et al. (1994)
Exon 7:
291 del G Frameshift (stoprcod /37) . . . Present study
331 CGGArCAGA G111R NlaIV Gu et al. (1993)
342 TGCrTGA C114X . . . Present study
Exon 8:
346 CGGrTGG R116W . . . Lee et al. (1991)
371 GTCrGAC V124D . . . Present study
Exon 9:
445 CGArTGA R149X . . . Kauppinen et al. (1995)
446 CGArCAA R149Q MboII Delfau et al. (1991)
446 CGArCTA R149L MboII Gu et al. (1994)
Exon 10:
499 CGGrTGG R167W . . . Gu et al. (1992)
500 CGGrCAG R167Q . . . Delfau et al. (1990)
500 del G Frameshift (stoprcod /98) . . . Present study
517 del 17 bp Frameshift (stoprcod /30) MspI Present study
517 CGGrTGG R173W MspI Lee and Anvret (1991)
518 CGGrCAG R173Q MspI Delfau et al. (1990)
530 CTGrCGG L177R . . . Mgone et al. (1992)
532 GACrAAC D178N . . . Present study
576–595 del 19 bp Frameshift (stoprcod /58) . . . Present study
593 TGGrTAG W198X NheI Lee and Anvret (1991)
612 CAGrCAT SD (del 9 bp exon 10) BamHI Delfau et al. (1991)
Intron 10:
612 /2 gtargca SD (del exon 10) . . . Present study
613 031 cacrcgc SA (del exon 11) . . . Present study
Exon 11:
625 GAGrAAG E209K Mnl I Grandchamp et al. (1989a )
639 TATrTAG Y213X . . . Present study
651 CAGrCAT Q217H . . . Present study
(continued )
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Table 2 (continued)
Restriction
Position Mutationa Sequence Modiﬁcationb Enzyme Reference
Intron 11:
652 01 del G SA (del exon 12) . . . Present study
652 01 cagrcac SA (del exon 12) . . . Present study
Exon 12:
667 GAArAAA E223K . . . Gu et al. (1994)
673 CGArTGA R225X . . . Kauppinen et al. (1995)
691–721 del 30 bp Truncated protein (?) BbvI Present study
713 CTGrCGG L238R BbvI Kauppinen et al. (1995)
715–716 del CA Frameshift (stoprcod /9) . . . Puy et al. (1996)
716 ins C Frameshift (stoprcod /10) . . . Present study
723 Duplication 21 bp 7-amino-acid repeat . . . Present study
730–731 del CT Frameshift (stoprcod /6) . . . Mgone et al. (1993)
734 CTTrCGT L245R . . . Delfau et al. (1991)
740 TGCrTTC C247F Fnu4HI Chen et al. (1994)
742 ins 8 bp (TTCGCTGC) Frameshift (stoprcod /10) . . . Gu et al. (1994)
748 GAArCAA E250Q . . . Lundin et al. (1995)
748 GAArAAA E250K . . . Gu et al. (1994)
749 GAArGTA E250V . . . Present study
749 GAArGCA E250A . . . Present study
755 GCCrGTC A252V EcoNI Mgone et al. (1993)
766 CACrTAC H256Y . . . Present study
771 CTGrCTA SD (del exon 12) BstNI Grandchamp et al. (1989a )
Intron 12:
771 /1 gtarata SD (del exon 12) . . . Puy et al. (1996)
772 01 cagrcaa SA (del exon 13) . . . Present study
Exon 13:
799 CGTGrATG V267M . . . Present study
809 GCTrGAT A270D . . . Present study
823 CAArTAA Q275X . . . Present study
Exon 14:
848 TGGrTAG W283X . . . Mgone et al. (1994)
849 TGGrTGA W283X . . . Schreiber et al. (1995)
854–855 del TA Frameshift (stoprcod /4) . . . Present study
863 TCArTAA S288X . . . Present study
900 del T Frameshift (stoprcod /15) . . . Delfau et al. (1991)
Intron 14:
912 /1 gtarata SD (del exon 14) RsaI Gu et al. (1993)
Exon 15:
913 ins C Frameshift (stoprcod /1) NlaIII Puy et al. (1996)
973 CGArTGA R325X NlaIII Petersen et al. (1995)
1004 GGCrGAC G335D . . . Present study
a Mutations occurring at the CpG dinucleotide are underlined.
b SD Å donor splice-site mutation; SA Å acceptor splice-site mutation; del Å deletion; ins Å insertion; and (stoprcod /X ) Å stop codon
occurs X codons downstream.
electrophoretic conditions, to increase the sensitivity to possibility of a second sequence variation and the possi-
bility that a detected base change is a rare polymor-as much as 89% (Kauppinen et al. 1995). Moreover,
the preliminary DGGE modelization step has the beneﬁt phism. To date, 10 intragenic polymorphisms have been
described, and it is noteworthy that no new discernibleof leading to a predictible result for the DNA fragment
under study, in contrast to SSCP or heteroduplex analy- polymorphism could be found by DGGE screening in
the 3.35 kb of the PBG deaminase gene from 405 Cauca-sis. But, whatever the molecular screening method used,
it must be stressed that all the 15 exons and exon/intron sian subjects.
This study underlines the considerable heterogeneityboundaries must be explored systematically, even if a
sequence variation is found in the course of the screening of molecular defects in AIP in France. A total of 78
different mutations were identiﬁed, including 33 thatstudy. This is necessary in order to eliminate both the
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consequent pathological features (Grandchamp et al.
1989c). Two of the 78 mutations occurred in the exon
1/intron 1 junction border, as elsewhere had been de-
scribed in a Finnish and a Dutch family with a variant
nonerythroid form of AIP (Grandchamp et al. 1989b,
1989c). A third mutation causing the nonerythroid form
of AIP—a GrA transition in the initiation codon of the
housekeeping transcript—has been characterized re-
cently (Chen et al. 1994) but was not found in any AIP
family in the present study.
Sixty percent of the mutations occurred in exons 10,
12, and 14. This ﬁnding could be helpful for the diagno-
sis of new AIP families, since analysis of these three
exons would have a high probability of success. In previ-
ous studies in other countries, exons 10 and 12 were
also often affected (at frequencies of 25% and 30%,
respectively) (for review, see Deybach and Puy 1995).
The distribution of the different types of mutations
shows a predominance of small mutational events re-
sponsible for AIP. Although the distribution of each nu-Figure 3 Molecular versus enzymatic diagnosis in AIP. AIP
cleotide has been reported to be homogeneous (20%–gene–carrier/–noncarrier status was compared for each relative, by
use of erythrocyte PBG deaminase activity and DNA analysis. Un- 29%; Yoo et al. 1993) along the PBG deaminase coding
blackened circles denote members of families who have the nonery- sequence, in this study a G and a C are involved, respec-
throid variant form of AIP; and black dots denote members of families tively, in 56% and 28% of single base substitutions. This
who have the classical form of AIP. Mean { SD erythrocyte PBG
disequilibrium could be explained by the high frequencydeaminase activity in controls (n Å 150) was 125 { 21 pmol of
(10/14) of mutated G’s in consensus splice sites and byuroporphyrin/h/mg Hb at 37C. The enzyme-activity cutoff for AIP
carriers was set at 85 pmol of uroporphyrin/h/mg Hb at 37C. When CpG dinucleotides, the latter of which are known hot
data from subjects with the nonerythroid form of AIP (n Å 23) were spots for mutations (Cooper and Youssouﬁan 1988).
excluded, mean { SD PBG deaminase activities in AIP patients (n Twenty-three mutations are due to the deamination ofÅ 110), asymptomatic AIP gene carriers (n Å 107), and normal rela-
a methylated cytosine, resulting in a GrA transition intives (n Å 145) were 72 { 8, 64 { 10, and 118 { 21, respectively.
17 cases and in a CrT transition in 6 cases.Concordance was found in 240/252 (95%) of AIP relatives.
Missense mutations were involved in 44% of cases.
However, data from previous multiple-case reports
(more often based on cDNA analysis) showed missensehad not been described elsewhere. Of these 33 new mu-
tations, 7 were splice-site disruptions further conﬁrmed mutations in 60% of the cases (for review, see Astrin and
Desnick 1994). This indicates the need for a prospective,by the presence of a shortened mRNA; of the 10 newly
described missense mutations, 8 affected strictly con- exhaustive, and standardized method using genomic
DNA to accurately describe the molecular epidemiologyserved amino acid residues and were located in regions
with a high homology between man, mouse, and Esche- of AIP in different populations.
On the basis of the E. coli–deduced PBG deaminaserichia coli. Direct or translated premature stop codons
were created by the 16 remaining new mutations. Most structure, it has been argued that the polypeptide chain
of the human enzyme is folded into three domains ofof the mutations were family speciﬁc, and only muta-
tions R167W, E250K, and W283X and the exon 14 approximately the same size (Jordan and Woodcock
1991; Brownlie et al. 1994; Wood et al. 1995). Figuredonor splice-site mutation had a slightly higher inci-
dence, of as much as 5%. These AIP families with the 4 shows the human PBG deaminase secondary structure,
with the position of all missense mutations found insame mutation could be followed though at least three
generations; usually they came from different parts of the French Caucasian AIP families studied. Interestingly,
most of the mutations affecting exon 12 were in an a-France. This ﬁnding differs from those of studies in Swe-
den and in The Netherlands, where suspected founder helix that links domains 1 and 3.
Two de novo events were also identiﬁed in the courseeffects have been reported (Lee and Anvret 1991; Gu et
al. 1993). The 78 mutations identiﬁed were distributed of the study. One patient had a GrA transition at posi-
tion 77 (amino acid substitution R26H), which alreadyin all the exons or exon/intron boundaries of the PBG
deaminase gene, except for exon 2; a molecular defect had been described in an AIP family with a classical
dominant inheritance (Llewellyn et al. 1993). In anotherin exon 2 would be expected to lead to PBG deaminase
deﬁciency restricted to its erythroid isoform and without family, a healthy relative was found to have a silent
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Figure 4 Schematic representation of PBG deaminase secondary structural elements, based on crystal structure of E. coli enzyme. Helices
are shown as cylinders, and the b sheets are shown as planes (in the manner of Jordan and Woodcock 1991; Brownlie et al. 1994; Wood et
al. 1995). The positions of the missense mutations characterized in French Caucasian AIP families, as determined by homology comparisons,
are indicated; note that most of them occur near the active site and affect arginine residues. Nine mutations, of the 35 missense mutations
reported, affect exon 12 at the a-helix hydrophobic interface between domains 1 and 3.
mutation affecting the third base of a GAC codon, at families with a different PBG deaminase gene mutation.
Although we excluded unsuitable samples (e.g., high re-position 108 (D36D; table 2); this de novo event was
also conﬁrmed by the normal genomic DNA sequence ticulocyte levels and children õ1 year old), in these 12
subjects PBG deaminase activities were within a narrowin both parents and by paternity investigation. Two de
novo mutations have been reported elasewhere, one in range (79–87) around the chosen cutoff value of 85
pmol uroporphyrin/h/mg Hb for AIP gene carriers (ﬁg.Finland (R195C; Kauppinen et al. 1995) and one in the
United Kingdom (R173W; Whatley et al. 1995). 3). This suggests that one must be cautious in the inter-
pretation of the enzymatic data in the overlap rangeSince an early and accurate recognition of asymptom-
atic carriers of AIP is essential for efﬁcient prevention between high heterozygote and low normal values. In
family studies, the detection of a known mutation in theof acute attacks, this study demonstrates the high efﬁ-
ciency of molecular-biology techniques in the diagnosis PBG deaminase gene is technically easy and reliable. For
patients with the nonerythroid AIP variant, the geneticof AIP, and it provides the opportunity to evaluate the
efﬁciency of erythrocyte PBG deaminase measurement test is superior to the erythrocyte assay, and it is the only
speciﬁc diagnostic method at the asymptomatic stage infor AIP gene–carrier detection. Results from AIP rela-
tives indicate that, despite its intrinsic probabilistic diag- classic AIP cases; thus it should be employed whenever
possible. However, the genetic approach may fail to de-nostic value, the erythrocyte PBG deaminase assay is a
sensitive test for detection of asymptomatic gene carriers tect the causal mutation in some cases (e.g., in the 12
classic AIP patients in this study), whereas the enzymatic(since it has 95% concordance with the molecular diag-
nosis; ﬁg. 3). However, one must emphasize that the 5% assay would still have a predictive value for ﬁnding carri-
ers in their respective families.discrepancy concerned 12 isolated subjects from 12 AIP
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normal erythrocyte porphobilinogen deaminase. Eur J ClinIn conclusion, we report the data from a prospective
Invest 19:415–418and extensive molecular study of AIP. We describe a
Grandchamp B, Picat C, Mignotte V, Wilson JHP, te Veldemutation-screening strategy, based on a sensitive and
K, Sandkuyl L, Romeo PH, et al (1989c) Tissue speciﬁcreproducible DGGE method that allowed (1) the charac-
splicing mutation in acute intermittent porphyria. Proc Natlterization of unknown mutations in new patients, (2)
Acad Sci USA 86:661–664
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